Sanofi Names Belén Garijo as New CEO, Effective After April Shareholder Meeting
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Sanofi ( (SNY) ) is now available.
Sanofi announced on February 12, 2026, that its Board of Directors decided on February 11 not to renew the director mandate of Chief Executive Officer Paul Hudson, whose tenure will end on February 17, 2026. Executive Vice President for General Medicines Olivier Charmeil will serve as interim CEO during the transition period.
The Board appointed former Merck KGaA chief executive and ex-Sanofi executive committee member Belén Garijo as the next CEO, with her term to begin after the April 29, 2026 annual general meeting, subject to her election as a director. Sanofi’s chairman highlighted Garijo’s track record in strategy execution and large-scale transformations, signaling a push to tighten governance, boost R&D productivity and innovation, and position the group for its next growth cycle in a rapidly evolving pharmaceutical landscape.
The most recent analyst rating on (SNY) stock is a Hold with a $51.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
The score is driven primarily by solid financial resilience and a constructive earnings outlook (growth, margin expansion, and buybacks). Valuation is supportive with a reasonable P/E and strong dividend, while weaker technical trend signals (below major moving averages and negative MACD) temper the overall rating.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D-driven, AI-powered biopharmaceutical company focused on discovering and developing medicines and vaccines that harness the immune system to treat and protect millions of patients worldwide. Listed on EuronEXT and Nasdaq, the group targets sustainable growth while addressing urgent healthcare, environmental and societal challenges through an innovative pipeline and global commercial footprint.
Average Trading Volume: 3,060,663
Technical Sentiment Signal: Hold
Current Market Cap: $118.3B
For detailed information about SNY stock, go to TipRanks’ Stock Analysis page.
